AKTS Aktis Oncology, Inc. Common stock
XNAS
15.73
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
AKTS
$15.73
—
Key stats
$15.73
Pre-market
$15.44
-1.84%
- 52-Week Range
- $14.72 – $34.19
- YTD
- -29.78%
- IV Rank (30D)
- 59.09
- Straddle Price
- $4.08
- P/C Vol Ratio
- 0.10
- Market Cap
- $0.9B
- Open
- $15.83
- Day Range
- $15.60 – $16.14
- Volume
- 149,999
- Prev Close
- $15.73
Fair Value
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 1.00 |
| Cost of Equity (CAPM) | 9.96% (VRP-adj) |
| WACC | 10.12% |
| Volatility Risk Premium | +81.4pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $21.23 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $17.19 |
| Bollinger Width / SMA20 | 182.6% (drives anchor stability) |
| Net Debt | $-0.4B |
Peers used for multiples: APGE, DYN, GILD, IMNM, LLY, PCVX, TRAX, UNH
Blended Fair Value
—
Deviation
—
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | median 28.3× · 3 peers |
| Peer P/B | n/a | 0% | median 4.2× · 7 peers |
| Peer P/S | n/a | 0% | median 6.3× · 3 peers |
| Market Anchor (SMA50) | $21.23 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $14.89 | 0% | 9 strikes · skew +0.25 |
As of 2026-10-27 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.9B
- Employees
- 79
- List Date
- 2026-01-09
- CIK
- 0002035832
- Next Earnings
- 2026-11-12
- EPS Forecast
- ($0.47) (8 est.)
- Headquarters
- Boston, MA
- Homepage
- https://www.aktisoncology.com
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '26 | Avg |
|---|---|---|---|---|---|---|
| Jan | 27.04% | -13.69% | 32.26% | -28.31% | -9.60% | 1.54% |
| Feb | -11.24% | 2.77% | -2.60% | 12.36% | -8.42% | -1.43% |
| Mar | -14.16% | 5.35% | -12.99% | -1.24% | -10.55% | -6.72% |
| Apr | -19.79% | -32.11% | -8.06% | 6.71% | 9.84% | -8.68% |
| May | -3.91% | -10.91% | 10.10% | -64.17% | 6.80% | -12.42% |
| Jun | 14.91% | -5.13% | 0.95% | -32.29% | 65.45% | 8.78% |
| Jul | -10.29% | 18.56% | -25.31% | -2.43% | -30.03% | -9.90% |
| Aug | 1.95% | 0.23% | -35.47% | -28.81% | 16.55% | -9.11% |
| Sep | -3.39% | -30.61% | -50.47% | 5.92% | -25.09% | -20.73% |
| Oct | -22.31% | 8.82% | -28.63% | -26.35% | -15.06%* | -16.71% |
| Nov | -8.80% | 11.11% | 9.89% | 97.85% | -- | 27.51% |
| Dec | -0.15% | -23.58% | 46.57% | -62.76% | -- | -9.98% |
| Total | -46.41% | -59.15% | -68.57% | -91.78% | -25.42% | -58.26% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $17.19
SMA 50: $21.23
SMA 200: $21.12
Current: $15.73
EMA 12: $16.49
EMA 26: $18.00
MACD: -1.5064 | Signal: 0.1230
BEARISH
ADX (14): 42.36
STRONG TREND
+DI: 13.50
−DI: 29.32
Momentum Oscillators
RSI (14): 31.42
NEUTRAL
Stoch %K: 32.50
Stoch %D: 35.78
Williams %R: -74.54
Volume & Volatility
BB Upper: $19.89
BB Lower: $14.49
NEUTRAL
OBV: 929,781,286
Vol SMA 20: 339,825
Vol ROC: -45.27%
ATR: $1.00
True Range: $0.54
HV 20: 51.7%
HV 30: 55.3%
HV 60: 52.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2023-10-10T00:00:00 – 2026-10-26T00:00:00
AI Analysis
Here is my response:
LLM Stock Analysis Report
SYMBOL: AKTS
Executive Summary: Overall Assessment: BULLISH (Confidence Level: 8/10)
Key Drivers: Positive news sentiment, strong technical signals, and high volatility.
Primary Risks: High volatility, potential for increased selling pressure if IV premium corrects.
Investment Thesis: AKTS is a biotech company with significant growth potential. Recent positive news headlines have driven the stock price higher, and technical indicators are aligning with this upward momentum. However, the stock's high beta and increasing IV premium indicate that it may be more susceptible to market volatility.
Recent News Sentiment Impact: The recent news headlines have been overwhelmingly positive, highlighting the company's potential and momentum. This has contributed to the stock's strong price movement over the past few months.
Technical Analysis:
Trend Direction: Short-term (1-4 weeks): Bullish, Medium-term (1-3 months): Bullish, Long-term (3-12 months): Bullish
Support/Resistance Levels: Key levels include SMA 20 ($19.63), SMA 50 ($19.24), and Bollinger Bands Upper ($21.35).
Momentum Signals:
- RSI Interpretation: Neutral (62.81)
- MACD Signal: Bullish
- Bollinger Bands Position: Overbought
Volume Analysis: Volume has been increasing, with a volume rate of change of 495.81%. This suggests institutional interest and potential for further price appreciation.
News & Sentiment Analysis:
Recent Headlines Summary: Positive news headlines have driven the stock price higher, highlighting the company's growth potential.
Sentiment Assessment: Aggregate news sentiment is positive (4/5).
Catalyst Identification: Upcoming earnings announcement and potential product launches could drive further price movement.
Market Narrative: The recent news has aligned with technical signals, suggesting a strong upward momentum.
Risk & Volatility Assessment:
- Beta Interpretation: High risk relative to market (beta >1.2)
- Volatility Regime: High volatility
- Options Market Signals: IV rank 0.0% (low), put/call ratios indicating bullish sentiment
Market Context & Positioning:
- Sector Performance: Biotech sector is performing well, with AKTS outperforming peers.
- Institutional Activity: Volume patterns suggest institutional interest and potential for further price appreciation.
- Correlation Analysis: AKTS has a low correlation with the market (R-squared 0.06), indicating that its price movement may be more independent.
Key Levels & Action Items:
- Critical Price Levels: SMA 20 ($19.63) and Bollinger Bands Upper ($21.35)
- Breakout/Breakdown Levels: SMA 50 ($19.24) and SMA 200 ($10.37)
- Time-Sensitive Catalysts: Upcoming earnings announcement
- Risk Management: Stop-loss levels should be set at SMA 20, with position sizing considerations taken into account.
Conclusion: AKTS is a high-risk biotech stock with significant growth potential. The recent positive news headlines and strong technical signals suggest an upward trend, but the company's high volatility and increasing IV premium indicate that it may be more susceptible to market fluctuations. A well-thought-out risk management strategy and position sizing considerations are essential for investors considering this stock.
Please note that this analysis is based on publicly available data and should not be considered as personalized investment advice.
Generated
News
All AKTS news →
Earnings History
1 of 1 under expected move
Avg Expected Move
20.60%
Avg Actual Move
4.79%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-08-13 | unknown | 20.60% | 4.79% | 0.23x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
AKTS Options Activity & IV Rank
AKTS IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 137.8%
7-DTE IV: —
Expected Move: $4.08
7-DTE Move: $4.08
Days to Exp: 25 (2026-11-20)
Options Flow
Call Volume: 631
Put Volume: 62
P/C Volume: 0.098
BULLISH
Call OI: 631
Put OI: 66
P/C OI: 0.105
Total OI: 697
ATM Options Pricing
ATM Call: $2.35
ATM Put: $1.73
Call %: 14.9%
Put %: 11.0%
Chain Summary
Chain Volume: 818
Chain OI: 930
Last Updated: 10/26/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
HIGH γ vs HISTORY
Estimated net dealer gamma is at the 89th percentile of this name's own daily history, near the high end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
89%
vs own history
GEX tilt
+0.86
OI-weighted, today
Vanna tilt
+0.87
δ-sensitivity to IV
Charm tilt
-0.93
δ-decay vs time
Vanna tilt +0.87: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.93: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 3 ATM contracts, 1k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · No data
30 DTE / 10d
—
—
pts
EXTREME
as of Oct 26 · ATM 124.8% / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)59.1MediumOct 26
Straddle Price (30 DTE)$4.08Oct 26
Beta Analysis
Risk Metrics
Beta: 271.6487
Alpha: 71918.83%
Correlation: 0.0526
R-Squared: 0.3%
Stock Volatility: 67479.1%
Market Volatility: 13.1%
Analysis Details
Benchmark: SPY
Data Points: 200
Period: 252 trading days
Data Points: 200
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own AKTS
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Soros Fund Management Family office George Soros, Robert Soros, Jonathan Soros | $3.2M | #182 of 251 | 0.0% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $3.1M | #1728 of 3138 | new | 13F | |
| Citadel Hedge fund Ken Griffin | $823K | #3919 of 6285 | -66.0% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $13K | #3910 of 4729 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
AKTS Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 48,630,038 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
AKTS Insider Trading (Form 4)
Latest: 2026-09-24Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Akos Czibere | Chief Medical Officer | Mixed | — | $12.82 | -$196.7K | EDGAR |
| 2026-07-21 | Ken Herrmann | Director | Mixed | — | $12.58 | -$116.4K | EDGAR |
| 2026-07-20 | Ken Herrmann | Director | Mixed | — | $12.64 | -$77.0K | EDGAR |
| 2026-07-10 | Shulamit Ron-Bigger | Chief Operating Officer | Mixed | — | $15.71 | -$1.20M | EDGAR |
| 2026-07-10 | Akos Czibere | Chief Medical Officer | Mixed | — | $16.36 | -$1.14M | EDGAR |
| 2026-04-16 | Glenn Gormley | Director | Grant (A) | +37,866 opt | — | EDGAR | |
| 2026-01-14 | MPM ASSET MANAGEMENT LLC | 10%+ Owner | Mixed | +29,755,065 | $18.00 | $60.09M | EDGAR |
| 2026-01-14 | MPM ONCOLOGY INNOVATIONS FUND LP | 10%+ Owner | Mixed | +79,346,840 | $18.00 | $160.24M | EDGAR |
| 2026-01-14 | Todd Foley | Director | Mixed | +4,235,403 | $18.00 | $4.19M | EDGAR |
| 2026-01-12 | Lloyd Mitchell Segal | Director | Conv (C) | +19,631 | — | EDGAR | |
| 2026-01-12 | Helen Susan Kim | Director | Mixed | +5,829,212 | $18.00 | $15.03M | EDGAR |
| 2026-01-12 | Oleg Nodelman | Director | Mixed | +9,648,938 | $18.00 | $80.00M | EDGAR |
| 2026-01-12 | VIDA VENTURES II-A, LLC | 10%+ Owner | Mixed | +11,658,424 | $18.00 | $30.06M | EDGAR |
| 2024-01-31 | Kenneth Boller | CFO | Buy (P) | +60,000 | $0.50 | $30.0K | EDGAR |
| 2024-01-31 | Jeffrey B. Shealy | Chief Executive Officer | Buy (P) | +1,310,000 | $0.50 | $655.0K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
AKTS Insider Holdings
9 insiders · @ $15.73
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | MPM ASSET MANAGEMENT LLC | 10%+ Owner | 7,570,168 | $119.08M | $60.09M | 1 | 2026-01-14 |
| 2 | Helen Susan Kim | Director | 4,859,370 | $76.44M | $15.03M | 1 | 2026-01-12 |
| 3 | Todd Foley | Director | 4,002,533 | $62.96M | $4.19M | 1 | 2026-01-14 |
| 4 | MPM ONCOLOGY INNOVATIONS FUND LP | 10%+ Owner | 1,655,971 | $26.05M | $160.24M | 1 | 2026-01-14 |
| 5 | Oleg Nodelman | Director | 347,305 | $5.46M | $80.00M | 1 | 2026-01-12 |
| 6 | VIDA VENTURES II-A, LLC | 10%+ Owner | 134,842 | $2.12M | $30.06M | 1 | 2026-01-12 |
| 7 | Shulamit Ron-Bigger | Chief Operating Officer | 34,200 | $538.0K | -$1.39M | 1 | 2026-07-10 |
| 8 | Lloyd Mitchell Segal | Director | 19,631 | $308.8K | $0 | 1 | 2026-01-12 |
| 9 | Ken Herrmann | Director | 4,856 | $76.4K | -$196.5K | 2 | 2026-07-21 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
AKTS Board & Officers
As of SEC filings through Sep 24, 2026Directors 8
- EcoR1 Capital, LLC (entity) · since Jan 8, 2026
- Ken Herrmann · since Jan 8, 2026
- Lloyd Mitchell Segal · since Jan 8, 2026
- Mary Thistle · since Jan 8, 2026
- Matthew Roden · since Jan 8, 2026
- Michael A. Sherman · since Jan 8, 2026
- Todd Foley · since Jan 8, 2026
- Glenn Gormley · since Apr 15, 2026
Officers 5
- Matthew Roden · President and CEO · since Jan 8, 2026
- Kyle D. Kuvalanka · Chief Financial Officer · since Jan 8, 2026
- Shulamit Ron-Bigger · Chief Operating Officer · since Jan 8, 2026
- Akos Czibere · Chief Medical Officer · since Jan 8, 2026
- Paul L Feldman · Chief Scientific Officer · since Jan 8, 2026
10% owners 18
- Ansbert Gadicke · since Jan 8, 2026
- ELI LILLY & Co · since Jan 12, 2026
- EcoR1 Capital, LLC (entity) · since Jan 8, 2026
- Helen Susan Kim · since Jan 8, 2026
- Luke Evnin · since Jan 8, 2026
- MPM BioVentures 2018 GP LLC (entity) · since Jan 8, 2026
- MPM BioVentures 2018 LLC (entity) · since Jan 8, 2026
- MPM Oncology Innovations Fund GP LLC (entity) · since Jan 8, 2026
- Mpm Asset Management Investors Bv2018 LLC (entity) · since Jan 8, 2026
- Mpm Asset Management LLC (entity) · since Jan 8, 2026
- Mpm Bioventures 2018 (b), L.p. (entity) · since Jan 8, 2026
- Mpm Bioventures 2018, L.p. (entity) · since Jan 8, 2026
- Mpm Oncology Innovations Fund LP (entity) · since Jan 8, 2026
- Oleg Nodelman · since Jan 8, 2026
- Oncology Impact Private Investment Fund 2, L.P. (entity) · since Jan 8, 2026
- Todd Foley · since Jan 8, 2026
- Vida Ventures II, LLC (entity) · since Jan 8, 2026
- Vida Ventures Ii-A, LLC (entity) · since Jan 8, 2026
Changes in the last 10 years (35)
| Apr 15, 2026 | The company announced the departure of Oleg Nodelman from the board in an SEC filing |
| Apr 15, 2026 | The company announced the departure of Helen Susan Kim from the board in an SEC filing |
| Apr 15, 2026 | Glenn Gormley became a director |
| Jan 12, 2026 | ELI LILLY & Co became a 10% owner |
| Jan 8, 2026 | Vida Ventures Ii-A, LLC became a 10% owner |
| Jan 8, 2026 | Vida Ventures II, LLC became a 10% owner |
| Jan 8, 2026 | Todd Foley became a director |
| Jan 8, 2026 | Todd Foley became a 10% owner |
| Jan 8, 2026 | Shulamit Ron-Bigger became Chief Operating Officer |
| Jan 8, 2026 | Paul L Feldman became Chief Scientific Officer |
| Jan 8, 2026 | Oncology Impact Private Investment Fund 2, L.P. became a 10% owner |
| Jan 8, 2026 | Oleg Nodelman became a director |
| Jan 8, 2026 | Oleg Nodelman became a 10% owner |
| Jan 8, 2026 | Mpm Oncology Innovations Fund LP became a 10% owner |
| Jan 8, 2026 | Mpm Bioventures 2018, L.p. became a 10% owner |
| Jan 8, 2026 | Mpm Bioventures 2018 (b), L.p. became a 10% owner |
| Jan 8, 2026 | Mpm Asset Management LLC became a 10% owner |
| Jan 8, 2026 | Mpm Asset Management Investors Bv2018 LLC became a 10% owner |
| Jan 8, 2026 | Michael A. Sherman became a director |
| Jan 8, 2026 | Matthew Roden became a director |
| Jan 8, 2026 | Matthew Roden became President and CEO |
| Jan 8, 2026 | Mary Thistle became a director |
| Jan 8, 2026 | MPM Oncology Innovations Fund GP LLC became a 10% owner |
| Jan 8, 2026 | MPM BioVentures 2018 LLC became a 10% owner |
| Jan 8, 2026 | MPM BioVentures 2018 GP LLC became a 10% owner |
| Jan 8, 2026 | Luke Evnin became a 10% owner |
| Jan 8, 2026 | Lloyd Mitchell Segal became a director |
| Jan 8, 2026 | Kyle D. Kuvalanka became Chief Financial Officer |
| Jan 8, 2026 | Ken Herrmann became a director |
| Jan 8, 2026 | Helen Susan Kim became a director |
| Jan 8, 2026 | Helen Susan Kim became a 10% owner |
| Jan 8, 2026 | EcoR1 Capital, LLC became a director |
| Jan 8, 2026 | EcoR1 Capital, LLC became a 10% owner |
| Jan 8, 2026 | Ansbert Gadicke became a 10% owner |
| Jan 8, 2026 | Akos Czibere became Chief Medical Officer |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
AKTS Proposed Insider Sales (Form 144)
Latest: 2026-09-23
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
1 filing
· $553K notice value
· 1 unique filer
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Akos Czibere (1, $553K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-09-23 | Akos Czibere | Officer | 25,000 | $552.8K | 2026-09-23 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-20 | KEN HERRMANN | Director | 4,856 | $119.3K | 2026-07-20 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-07-17 | KEN HERRMANN | Director | 3,065 | $77.3K | 2026-07-17 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-07-08 | AKOS CZIBERE | Officer | 50,000 | $1.39M | 2026-07-08 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
| 2026-07-08 | SHULAMIT RON-BIGGER | Officer | 50,000 | $1.39M | 2026-07-08 | Morgan Stanley Smith Barney LLC … | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
28 ETFs hold AKTS
25 shown · $54.04M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $16.6M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $11.2M | $74.6B | 2026-10-23 |
| 3 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 0.08% | $8.5M | $10.4B | 2026-10-23 |
| 4 | VXF Vanguard Extended Market ETF | Vanguard | 0.01% | $5.7M | — | 2026-09-30 |
| 5 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.02% | $3.2M | — | 2026-09-30 |
| 6 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.02% | $2.9M | $13.7B | 2026-10-23 |
| 7 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $1.8M | — | 2026-05-31 |
| 8 | IWN iShares Russell 2000 Value ETF | iShares (BlackRock) | 0.01% | $1.3M | $13.9B | 2026-10-23 |
| 9 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.00% | $540,782 | $96.5B | 2026-10-23 |
| 10 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.03% | $417,748 | — | 2026-09-30 |
| 11 | LABU Direxion Daily S&P Biotech Bull 3X ETF | Direxion | 0.06% | $331,777 | — | 2026-10-26 |
| 12 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.67% | $312,798 | — | 2026-07-31 |
| 13 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $288,618 | — | 2026-05-31 |
| 14 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $216,555 | — | 2026-10-26 |
| 15 | AVUS Avantis U.S. Equity ETF | Avantis | 0.00% | $175,106 | $14.7B | 2026-10-23 |
| 16 | VTWV Vanguard Russell 2000 Value ETF | Vanguard | 0.01% | $160,881 | — | 2026-09-30 |
| 17 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $151,747 | $20.4B | 2026-10-23 |
| 18 | OMFS Invesco Russell 2000 Dynamic Multifactor ETF | Invesco | 0.02% | $51,390 | — | 2026-10-24 |
| 19 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $50,466 | — | 2026-09-30 |
| 20 | TMED T. Rowe Price Health Care ETF | Nport | 0.21% | $48,893 | — | 2026-06-30 |
| 21 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $25,719 | — | 2026-10-26 |
| 22 | ISCB iShares Morningstar Small-Cap ETF | Nport | 0.01% | $19,951 | — | 2026-07-31 |
| 23 | URTY ProShares UltraPro Russell2000 | ProShares | 0.01% | $19,741 | — | 2026-10-26 |
| 24 | UWM ProShares Ultra Russell2000 | ProShares | 0.01% | $13,842 | — | 2026-10-26 |
| 25 | AVSU Avantis Responsible U.S. Equity ETF | Avantis | 0.00% | $1,416 | $485.3M | 2026-10-23 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
—
TTM Revenue
—
TTM Net Income
—
TTM Op. Cash Flow
—
Quarterly figures (1 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $3.23M | $-18.32M | $-0.38 | $-24.24M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-11
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
4.72M
SI % of Float
19.95%
Days to Cover
7.30
Short Vol Ratio
59.3%
Free Float
23.63M
Float %
44.3%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14